Obesity Research and Clinical Practice 2009-Nov
Rimonabant-induced catatonia in schizophrenia: A case report.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
Palabras clave
Abstracto
CONCLUSIONS
Patients with psychiatric illness have higher rates of mortality and medical co-morbidity related to increased rates of diabetes mellitus and cardiovascular disease. Rimonabant, a cannabinoid receptor (CB1) antagonist, is an anti-obesity agent and decreases risk for metabolic syndrome. Though there are reports of rimonabant associated with adverse psychiatric events like depression, rimonabant-induced catatonia is not reported. In this first time report, we describe a patient with schizophrenia developing catatonia possibly due to rimonabant.:
